Edition:
United States

Stemline Therapeutics Inc (STML.O)

STML.O on Consolidated Issue listed on NASDAQ Capital Market

8.55USD
27 Mar 2017
Change (% chg)

-- (--)
Prev Close
$8.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
340,696
52-wk High
$14.60
52-wk Low
$4.06

Latest Key Developments (Source: Significant Developments)

Stemline Therapeutics Q4 loss per share $0.56
Thursday, 16 Mar 2017 07:26pm EDT 

Stemline Therapeutics Inc : Stemline therapeutics reports fourth quarter 2016 financial results . Q4 loss per share $0.56 . Q4 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S .Qtrly grant revenue $299,401 versus $205,651.  Full Article

Stemline Therapeutics Q2 loss per share $0.52
Thursday, 4 Aug 2016 07:59am EDT 

Stemline Therapeutics Inc : Q2 loss per share $0.52 . Stemline Therapeutics reports second quarter 2016 financial results and highlights recent clinical progress .Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article

Stemline Therapeutics reports Q1 loss per share $0.51
Monday, 9 May 2016 08:00am EDT 

Stemline Therapeutics Inc : Stemline Therapeutics reports first quarter 2016 financial results . Q1 loss per share $0.51 .Q1 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.  Full Article

Stemline Therapeutics Inc announces SL-401 receives EU Orphan Drug designation for treatment of BPDCN
Monday, 2 Nov 2015 08:01am EST 

Stemline Therapeutics Inc:Says European Medicines Agency has granted Orphan Drug designation to SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm.Stemline is evaluating SL-401 in multiple clinical programs, including an ongoing pivotal trial in BPDCN as well as trials in additional hematological cancers.  Full Article

Stemline Therapeutics Inc announces SL-401 receives eu orphan drug designation for treatment of acute myeloid leukemia
Thursday, 10 Sep 2015 08:00am EDT 

Stemline Therapeutics Inc:Announces SL-401 receives EU orphan drug designation for treatment of acute myeloid leukemia (AML).Says is evaluating SL-401 in three trials across 7 different indications.  Full Article

More From Around the Web

BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN

* Stemline Therapeutics announces completion of enrollment in stage 3 of the sl-401 pivotal trial in bpdcn